Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder.

Pharmacopsychiatry - 1 Sept 2016

Ng C H, Bousman C, Smith D J, Dowling N, Byron K, King J, Sarris J

Abstract excerpt

No studies to date have evaluated SLC6A2 and SLC6A4 genetic polymorphisms influencing antidepressant response to desvenlafaxine. We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. Results revealed that homozygotes for the SLC6A4 HTTLPR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Depressive Disorder, Major

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Norepinephrine Plasma Membrane Transport Proteins

Share to Pharmacogenetics

Share to Pilot Projects

Share to Polymorphism, Single Nucleotide

Share to Serotonin Plasma Membrane Transport Proteins

Source

Identifiers

PMID: 27023264
DOI: 10.1055/s-0042-103968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder.PMID 27023264Read ↗

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depressionSemantic proximity Read ↗

SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.Semantic proximity Read ↗

Polymorphisms in the 5-Hydroxytryptamine 2A Receptor and CytochromeP4502D6 Genes Synergistically Predict Fluvoxamine-Induced Side Effects in Japanese Depressed PatientsSemantic proximity Read ↗

Association of Serotonin Transporter Gene 5HTTLPR rs25531 Polymorphism With Escitalopram Efficacy in Patients With Major Depressive Disorder.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Serotonin transporter gene polymorphisms and sertraline response in major depression patients.Semantic proximity Read ↗

Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.Semantic proximity Read ↗

Serotonin Pathway Polymorphisms and the Treatment of Major Depressive Disorder and Anxiety DisordersSemantic proximity Read ↗

Association Study Between Serotonin Transporter Gene and Fluoxetine Response in Mexican Patients With Major Depressive DisorderSemantic proximity Read ↗

Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.